Drug use in pregnancy;Drogen in der schwangerschaft

Therapeutische Umschau

Volumn 62, Issue 1, 2005, Pages 29-35

  Von Mandach, U ^a  

^a UNIVERSITÄTSSPITAL ZÜRICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALCOHOL; CANNABIS; CARBON MONOXIDE; COCAINE; DIAMORPHINE; LYSERGIDE; METHADONE; MORPHINE; OPIATE; TETRAHYDROCANNABINOL;

CONGENITAL MALFORMATION; DEVELOPMENTAL DISORDER; DRUG ABUSE; FETAL ALCOHOL SYNDROME; FETUS ECHOGRAPHY; HUMAN; INTRAUTERINE GROWTH RETARDATION; LOW BIRTH WEIGHT; NERVOUS SYSTEM DEVELOPMENT; NEWBORN PERIOD; PREGNANCY; PREMATURE LABOR; REVIEW; SMOKING; SOLUTIO PLACENTAE; SPONTANEOUS ABORTION; STILLBIRTH; TOBACCO; VASOCONSTRICTION; WITHDRAWAL SYNDROME;

ABNORMALITIES, DRUG-INDUCED; FEMALE; FETAL DISEASES; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PREGNANCY; PREGNANCY COMPLICATIONS; RISK ASSESSMENT; RISK FACTORS; SUBSTANCE-RELATED DISORDERS; WOMEN'S HEALTH;

EID: 12444317531     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930.62.1.29     Document Type: Review

References (61)

1. Fuchs A-R, Husslein P, Sumulong L, Micha JP, Dawood MY, Fuchs F. Plasma levels of oxytocin and 13, 14-dihydro-15-keto-prostaglandin F2a in preterm labor and the effect of ethanol and ritodrine. Am J Obstet Gynecol 1982a; 144: 753-9.
2. Jacobson JL, Jacobson SW. Prenatal alcohol exposure and neurobehavioral development: where is the treshold. Alcohol Health Res World 1994; 18: 30-6.
3. Alcohol consumption among pregnant and childbearing aged women. United States, 1991 and 1995. MMWR 1997; 46: 346-50.
4. Bowden R, Rust D. A review of fetal alcohol syndrome for health educators. J Health Educ 2000; 31: 231-7.
5. Konovalov HV, Kovetsky NS, Bobryshev YV, Ashwell KWS. Disorders of brain development in the progeny of mothers who used alcohol during pregnancy. Early Hum Dev 1997; 48: 153-66.
6. Cartwright MM, Smith SM. Stage-dependent effects of ethanol on cranial neural crest cell development: partial basis for the phenotypic variations observed in fetal alcohol syndrome. Alcohol Clin Exp Res 1995; 19: 1454-62.
7. Taylor CL, Jones KL, Jones MC, Kaplan GW. Incidence of renal anomalies in children prenatally exposed to ethanol. Pediatrics 1994; 94: 209-12.
8. Flores-Huerta S, Hernandez-Montes H, Argote RM, Villalpando S. Effects of ethanol consumption during pregnancy and lactation on the outcome and postnatal growth of the offspring. Ann Nutr Metab 1992; 36: 121-8.
9. Schöneck U, Spohr HL, Willms J, Steinhausen HC. Alkoholkonsum und intrauterine Dystrophie. Monatsschr Kinderheilkd 1992; 140: 34-41.
10. Abel EL, Sokol RJ. A revised conservative estimate of the incidence of FAS and its economic impact. Alcohol Clin Exp Res 1991; 15: 514-24.
11. Garcia Gil L, Romero J, Ramos JA, Fernandez Ruiz JJ. Cannabinoid receptor binding and mRNA levels in several brain regions of adult male and female rats perinatally exposed to delta9-tetrahydrocannabinol. Drug Alcohol Depend 1999; 55: 127-36.
12. Rehm J. Konsumformen und Verbreitung illegaler Drogen in der Schweiz. In: Fahrenkrug H. et al. (Hsg.). Illegale Drogen in der Schweiz 1990-1993. Zürich: Seismo-Verlag, 1995; 13-34.
13. Murthy NVA, Melville GN, Wynter HH. Contractile responses of uterine smooth muscle to acetylcholine and marihuana extract. Int J Gynaecol Obstet 1983; 21: 223-6.
14. Bonnin A, de Miguel R, Hernandez ML, Ramos JA, Fernandez-Ruiz JJ. The prenatal cannabis exposure to delta 9-tertrahydrocannabinol affects the gene expression and the activity of tyrosine hydroxylase during early brain development. Life Sci 1995; 56: 2177-84.
15. Navarro M, Rodriguez de Fonesca F, Hernandez ML, Ramos JA, Fernandez-Ruiz JJ. Motor behaviour and nigrostriatal dopaminergic activity in adult rats perinatally exposed to cannabinoids. Pharmacol Biochem Behav 1994; 47: 47-53.
16. Walters DE, Carr LA. Changes in brain catecholamine mechanisms following perinatal exposure to marihuana. Pharmacol Biochem Behav 1986; 25: 763-8.
17. Fried PA. Adolescents prenatally exposed to marijuana: examination of facets of complex behaviours and comparisons with the influence of in utero cigarettes. J Clin Pharmacol 2002; 42: 97S-102S.
18. Day NL, Richardson GA, Goldschmidt L, Robles N, Taylor PM, Stoffer DS, Cornelius MD, Geva D. Effect of prenatal marijuana exposure on the cognitive development of offspring at age three. Neurotoxicol Teratol 1994; 16: 169-75.
19. Fried PA. Postnatal consequences of maternal marijuana use. NIDA Res Monogr 1985; 59: 61-72.
20. Annual report on the state of the drugs problems in the European Union 2001. http://www.doh.gov.uk/drugs/drugreport2001;pdf
21. Fajemirokun-Odudeyi O, Lindow SW. Obstetric implications of cocain use in pregnancy, a literature review. Eur J Obstet Gynecol Reprod Biol 2004; 112: 2-8.
22. Frank DA, Jacobs RR, Beeghly M, Augustyn M, Bellinger D, Cabrai H, Heeren T. Level of prenatal cocaine exposure and scores on the Bayley Scales of Infant Development: modifying effects of caregiver, early intervention, and birth weight. Pediatrics 2002; 110: 1143-52.
23. Frank DA, Augustyn M, Knight WG, Pell T, Zuckerman B. Growth, development and behaviour in early childhood following prenatal cocaine exposure: a systematic review. JAMA 2001; 285: 1613-25.
24. Chasnoff IJ, Anson A, Hatcher R, Stenson H, Iaukea K, Randolph LA. Prenatal exposure to cocaine and other drugs. Outcome at four to six years. Ann N Y Acad Sci 1998; 846: 314-28.
25. Ho E, Karimi-Tabesh I, Koren G. Characteristics of pregnant women who use ecstasy (3,4-methylenedioxymethamphetamine. Neurotoxicol Teratol 2001; 23: 561-7.
26. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA. Positron emission tomographic evidence of toxic effect of MDMA (Ecstasy) on brain serotonin neurons in human beings. Lancet 1998; 352: 1433-7.
27. Kramer K, Azmitia EC, Whitaker-Azmitia PM. In vitro release of [3H]5-hydroxytryptamine from fetal and maternal brain by drugs of abuse. Dev Brain Res 1994; 78: 142-6.
28. Green AR, Mechan AO, Elliott JM, O' Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, «ecstasy»). Pharmacol rev 2003; 55: 463-508.
29. Green AR, Goodwin GM. Ecstasy and neurodegeneration. BMJ 1996; 312: 1493-4.
30. Colado MI, O'Shea E, Granados R, Misra A, Murray TK, Green AR. A study of the neurotoxic effect of MDMA (ecstasy) on 5-HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy. Br J Pharmacol 1997; 121: 827-33.
31. McElhatton PR, Bateman DN, Evans C, Pughe KR, Worsley AJ. Does prenatal exposure to ecstasy cause congenital malformations? A prospective follow-up of 92 pregnancies. Br J Clin Pharmacol 1998; 45: 184.
32. McElhatton PR, Bateman DN, Evans C, Pughe KR, Thomas SH. Congenital anomalies after prenatal ecstasy exposure. Lancet 1999; 354: 1441-2.
33. van Tonningen-van Driel MM, Garbis-Berkvens JM, Reuvers-Lodewijks WE. Pregnancy outcome after ecstasy use; 43 cases followed by the teratology information service of the national institute for public health and environment. Ned Tijdschr Geneeskd 1999; 143: 27-31.
34. Von Mandach U, Rabner MM, Wisser J, Huch A. LSD and cannabis abuse in early pregnancy with good perinatal outcome. Case report and review of the literature. Gynäkol Geburtshilfliche Rundsch 1999; 39: 125-9.
35. Cohen MM, Hirschhorn K, Frosch WA. In vivo and in vitro chromosomal damage induced by LSD-25. N Engl J Med 1967; 277: 1043-9.
36. Robinson JT Chitham RG, Greenwood RM, Taylor JW. Chromosome aberrations and LSD. A controlled study in 50 psychiatric patients. Br J Psychiat 1974; 125: 238-44.
37. Corey MJ, Andrews JC, McLeod MJ, Maclean JR, Wilby WE. Chromosome studies on patients (in vivo) and cells (in vitro) treated with lysergic acid diethylamide. N Engl J Med 1970; 282: 939-43.
38. Emerit I, Roux C, Feingold J. LSD: no chromosomal breakage in mother and embryos during rat pregnancy. Teratology 1972; 6: 71-4.
39. Alexander GJ, Miles BE, Gold GM, Alexander RB. LSD: Injection early in pregnancy produces abnormalities in offspring of rats. Science 1967; 157: 459-60.
40. Alexander GJ, Gold GM, Miles BE. Lysergic acid diethylamide intake in pregnancy: fetals damage in rats. J Pharmacol Exp Ther 1970; 173: 48-59.
41. Aase JM, Laestadius N, Smith DW. Children of mothers who took L.S.D. in pregnancy. Lancet 1970; 1: 100-01.
42. Jacobson CB, Berlin CM. Possible reproductive detriment in LSD users. JAMA 1972; 222: 1367-73.
43. Ibe M, Knolle P, Beck Th, Meyer zum Büschenfelde KH, Gerken G. HIV und Schwangerschaft: Risiken der Übertragung und therapeutische Möglichkeiten. Gynäkol Geburtshilfliche Rundsch 1996; 36. 188-93.
44. Shafer DA, Xie Y, Falek A. Detection of opiate-enhanced increases in DNA damage, HPRT mutants, and the mutation frequency in human HUT-78 cells. Environ Mol Mutagen 1994; 23: 37-44.
45. Stiene-Martin A, Gurwell JA, Hauser KF. Morphine alters astrocyte growth in primary cultures of mouse glial cells. Evidence for a direct effect of opiates on neural maturation. Brain Res Dev Brain Res 1991; 60: 1-7.
46. Ricalde AA, Hammer RP. Perinatal opiate treatment delays growth of cortical dendrites. Neurosci Lett 1990; 115: 137-43.
47. Berghella V, Lim PJ, Hill MK, Cherpes J, Chennat J, Kaltenbach K. Maternal methadone dose and neonatal withdrawal. Am J Obstet Gynecol 2003; 189: 312-7.
48. Greene CM, Goodman MH. Neonatal abstinence syndrome. Strategies for care of the drug-exposed infant. Neonatal Netw 2003; 22: 15-25.
49. Nanovskaya TN, Deshmukh SV, Nekhayeva IA, Zharikova OL, Hankins GD, Ahmed MS. Methadone metabolism by human placenta. Biochem Pharmacol 2004; 68: 583-91.
50. Sinha C, Ohadike P, Carrick P, Paiaudeau P, Armstrong D, Lindow SW. Neonatal outcome following maternal opiate use in late pregnancy. Int J Gynaecol Obstet 2001; 74: 241-6.
51. Wang EC, Methadone treatment during pregnancy. J Obstet Gyecol Neonatal Nurs. 1999; 28: 615-22.
52. Chiba M, Masironi R. Toxic and trace elements in tobacco and tobacco smoke. Bull World Health Organ 1992; 70: 269-75.
53. Seltzer V. Smoking as a risk factor in the health of women. Int J Gynaecol Obstet 2003; 82: 393-7.
54. Soothill PW, Morafa W, Ayida GA, Rodeck CH. Maternal smoking and fetal carboxyhaemoglobin - Werte. Br J Obstet Gynaecol 1996; 103: 78-82.
55. Lampl M, Kuzawa CW, Jeanty P. Prenatal smoke exposure alters growth in limb proportions and head shape in the midgestation human fetus. Am J Hum Biol 2003; 15: 533-46.
56. Fried PA, Watkinson B. Visuoperceptual functioning differs in 9- to 12-year olds prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol 2000; 22: 11-20.
57. Frydman M. The smoking addiction of pregnant women and the consequences of their offsprings intellectual development. J Environ Pathol Toxicol Oncol 1996; 15: 169-72.
58. Mc Carthney JS, Fried PA, Watkinson B. Central auditory processing in school - age children prenatally exposed to cigarette smoke. Neurotoxicol Teratol 1994; 16: 269-76.
59. Stocks J, Dezateux C. The effect of parenteral smoking on lung function and development during infancy. Respirology 2003; 8: 266-85.
60. Kandel DB, Wu P, Davies M. Maternal smoking during pregnancy and smoking by adolescent daughters. Am J Public Health 1994; 84: 1407-13.
61. Lichtensteiger W, Schlumpf M, Ribary U. Pharmacological modifications of neuroendocrine ontogenesis. Development of receptors, nicotine and catecholamines. Ann Endocrinol Paris 1987; 48: 393-9.